New Report: Medical Cannabis Prices in Germany Dropped in 2024, and Self-Paying Patients Reaped the Benefits
Frankfurt a.M., January 23, 2025 – According to a new report by Frankfurt, Germany-based medical cannabis company and telehealth platform Bloomwell GmbH (Bloomwell), medical cannabis was more affordable than ever before in 2024, with grams dropping to an all-time-low price in the fourth quarter.
In addition, the number of prescriptions issued has risen rapidly following the reclassification of cannabis as a non-narcotic, which went into effect on April 1, 2024. The latest data illustrates increased patient access and a steady supply to meet the growing demand for legal cannabis to be prescribed for common and chronic ailments like other frequently used Rx medications.
Summary of Results:
- After April 1, 2024 (the start of reclassification), cannabis prices per gram rose for a short time, but have fallen continuously since June and reached new lows in the fourth quarter.
- In October and November, select medical cannabis strains could be purchased at an all-time-low price of 3.99 Euros per gram.
- The average price fell to 8.35 Euros per gram in November (down from 9.27 Euros in January 2024).
- The number of prescriptions issued in December was more than 1,000 percent higher than in March 2024, indicating a rapid rise in the number of self-paying patients who are responsible for the full cost of their treatment.
- The variety of medical cannabis products dispensed by pharmacies more than doubled in 2024.
Titled “The Cannabis Barometer – 2024 Medical Cannabis Market Trends in Germany,” this is the latest in a series of real-world data-driven reports compiled by Bloomwell, which prioritizes industry transparency for all stakeholders. In September 2024, Bloomwell released the results of a representative survey revealing reasons why Germans use cannabis: the vast majority – 94 percent – of respondents reported they consume cannabis for at least one medical or health reason.
In an analysis of the latest findings, Dr. Julian Wichmann, Co-Founder and CEO of Bloomwell GmbH (“Bloomwell”) stated:
“Most people who consume cannabis in Germany do so for medical or health-related reasons. Given this reality, accessible medical cannabis therapy is crucial for public health. Digital platforms have made it possible for patients to access reliable, medically supervised cannabis treatments that meet pharmaceutical standards. Concerns about severe adverse effects have proven to be unfounded; in fact, medical cannabis typically has milder side effects than many medications used to treat common conditions like sleep disorders, chronic pain, and migraines. It can also be a sensible alternative to treat conditions that currently lack other forms of prescription medications, such as sleep disorders.”
Niklas Kouparanis, Co-Founder and CEO of Bloomwell Group, the holding company for Bloomwell GmbH, expounded:
“We are at the very beginning of a new era. Cannabis was a widely used remedy hundreds of years ago. After decades of stigmatization, the German government has ushered in a change in our country that also serves as a model of progressive policies for other European countries. Germany’s medical cannabis industry made great strides in 2024 and has become more equipped to service new patients. Despite the rapid increase in cannabis patients, companies, doctors and pharmacies have ensured a secure supply. It is now up to the incoming federal government to continue to shape the regulatory framework in such a way that jobs continue to be created, investors are given security and innovation is promoted so that patients continue to benefit from cost-effective access to therapy. Cannabis telemedicine is one of the few positive examples of digital innovation in the often inefficient German healthcare system, which at times leaves patients in the lurch, straddled with high costs, overwhelming bureaucratic and logistical processes, and an overall lack of access. The digitization of medical cannabis has been a true bright spot, and at Bloomwell, we’re looking forward to continuing to expand our patient reach and make the entire journey more seamless for those in need, along with physicians, pharmacies and wholesalers.
To compile the report, Bloomwell Group evaluated six-figure prescriptions that self-paying cannabis patients had submitted to partner pharmacies via the Bloomwell digital platform.
